The UK life sciences industry is burgeoning and, thanks in part to the role played by Covid in supercharging a range of sectors, it is on a path toward further expansion. Rishi Sunak, the Prime Minister, recently stated his ambition for the country to become a life sciences ‘superpower’.
However, at a time of unprecedented development, the industry also finds itself at the center of a skills shortage that threatens to stall, or even halt, its trajectory.
This skills gap is not only a
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
S&T Researchers Developing 3D-Printed Dressings for Better Wound Care
What You Should Know:
- Missouri University of Science and Technology researchers are developing new 3D-printed hydrogel dressings to speed up and improve the healing process for patients with second-degree burns. The research team published an article covering their latest findings in the International Journal of Bioprinting in July.
- Hydrogels are typically part of the care regimen for patients with severe burns, but what separates S&T’s research from standard hydrogels is that the
Read More
M&A: New Day Diagnostics to Acquire the Assets of Epigenomics AG
What You Should Know:
New Day Diagnostics LLC announced it has entered into an agreement to acquire the assets of Epigenomics AG, a molecular diagnostics company focused on blood testing for the early detection of cancer.Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker
Read More
NABP, IBM Partner to Build Platform to Protect Drug Supply Chain
What You Should Know:
The National Association of Boards of Pharmacy® (NABP®) and IBM Consulting are pleased to announce their collaboration to build Pulse by NABP™, a new digital platform that is intended to bring visibility to the drug supply chain and help protect patients from counterfeit or substandard prescription medications.Launching later in the summer of 2023, the platform is designed to facilitate manufacturers, wholesalers, pharmacies, and regulators to identify
Read More
ALZpath Secures Funding for Blood-Based Biomarker Testing for Alzheimer’s Disease Detection
What You Should Know:
- ALZpath, a developer of blood-based diagnostic biomarker testing for Alzheimer's disease detection receives funding from the Alzheimer’s Drug Discovery Foundation (ADDF)’s Diagnostics Accelerator to accelerate the clinical availability of ALZpathDx as a laboratory developed test (LDT).
- ALZpathDx is a novel, proprietary assay for blood-based measurement of phosphorylated tau at threonine 217 (pTau217), a highly accurate, diagnostic biomarker for
Read More
SiPhox Health Secures $27M for Lab-Grade Home Health Testing with Silicon Photonics
What You Should Know:
- Today, SiPhox Health, a Burlington, MA-based company building the next generation of lab-grade home health testing with silicon photonics raises $27M in funding, including a $10M Seed led by Khosla Ventures and Y Combinator, and a $17M Series A led by Intel Capital.
- The SiPhox Home and Health testing systems offer innovative and efficient blood collection solutions for consumers, healthcare systems, pharmaceutical companies, and research teams focusing on
Read More
The Problem With Modern Disinfectants & What The Future of Infection Protection Should Look Like
Keeping surfaces pathogen-free is crucial in preventing the transmission of diseases and infections. Pathogens are microorganisms that can cause illness, and they can easily spread from contaminated surfaces to people who come into contact with those surfaces. This is a major concern in healthcare settings such as hospitals, where pathogens can spread easily and cause infections in vulnerable patients. In addition, pathogen spread can also occur in public places such as schools, workplaces, and
Read More
Eli Lilly Acquires Obesity Drug Maker Versanis for $1.9B
What You Should Know:
Eli Lilly announced an agreement to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases for $1.925B in cash. Versanis' lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study alone and in combination with
Read More
Causaly Secures $60M to Accelerate AI-Powered Biomedical Research
What You Should Know:
Causaly, the leading AI platform for biomedical research raises $60M in Series B funding led by ICONIQ Growth, with participation from Index Ventures, Marathon Venture Capital, EBRD, Pentech Ventures and Visionaries Club. Strategic individuals also participated in the round, including Alex Gorsky (former Chairman and CEO of Johnson & Johnson) and Olivier Pomel (CEO and Co-Founder of Datadog). The investment brings the total funding raised to $93 million,
Read More
Israel Innovation Authority to Invest $31M to Establish R&D Infrastructure Center for Bio-Chips-Based Bio-Devices
What You Should Know:
The Israel Innovation Authority announced today a NIS 113M ($31M USD) investment for the establishment of a center that will provide research and development (R&D) infrastructure for bio-devices based on bio-chips. The investment is part of the National Bio-Convergence Program.Bio-convergence represents the integration of biology and life sciences with engineering and software technologies. The investment is directed at companies dedicated to developing key
Read More
